The new coronary vaccine, i.e. the new coronary virus vaccine, has been successfully developed. At present, the new coronary vaccines approved for marketing in China mainly include the new coronary virus inactivated vaccine (Vero cell), the recombinant new coronary virus vaccine (adenovirus vector type 5) and the recombinant new coronary virus vaccine (CHO cell). 1. New inactivated coronavirus vaccine (Vero cells): its main active ingredient is the inactivated new coronavirus. 2. Recombinant New Coronavirus Vaccine (Adenovirus 5 Vector): Its active ingredient is recombinant replication-deficient human adenovirus 5, which expresses the S protein of the new coronavirus. 3. Recombinant New Coronavirus Vaccine (CHO cells): It is an adenovirus vector vaccine, and its main active ingredient is the NCP-RBD protein of the receptor-binding region of the novel coronavirus spiny glycoprotein. Vaccination with the above vaccines can stimulate the body to develop immunity against the new coronavirus, and is used to prevent diseases caused by the new coronavirus, and must be used in accordance with the national immunization plan and relevant immunization strategies, and under the guidance of the competent national health authorities and the relevant regulatory bodies for disease control.